Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aortic Valve Stenosis | 3 | 2024 | 334 | 0.990 |
Why?
|
| Cardiovascular Diseases | 5 | 2025 | 2038 | 0.910 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2017 | 48 | 0.870 |
Why?
|
| Mitral Valve Stenosis | 1 | 2024 | 34 | 0.850 |
Why?
|
| Patient Selection | 3 | 2025 | 713 | 0.830 |
Why?
|
| Transcatheter Aortic Valve Replacement | 2 | 2024 | 207 | 0.820 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2024 | 180 | 0.740 |
Why?
|
| Echocardiography | 3 | 2024 | 1115 | 0.660 |
Why?
|
| Ventricular Function, Left | 1 | 2023 | 521 | 0.630 |
Why?
|
| Women's Health | 2 | 2011 | 138 | 0.620 |
Why?
|
| Registries | 2 | 2025 | 1540 | 0.590 |
Why?
|
| Heart Valve Prosthesis | 2 | 2014 | 295 | 0.570 |
Why?
|
| Heart Diseases | 3 | 2012 | 490 | 0.550 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 303 | 0.550 |
Why?
|
| Mitral Valve | 2 | 2024 | 250 | 0.550 |
Why?
|
| Menopause | 1 | 2017 | 84 | 0.520 |
Why?
|
| Blood Pressure | 3 | 2017 | 1338 | 0.430 |
Why?
|
| beta-Alanine | 1 | 2014 | 7 | 0.420 |
Why?
|
| Antithrombins | 1 | 2014 | 47 | 0.410 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 416 | 0.400 |
Why?
|
| Heart Failure | 3 | 2023 | 2289 | 0.400 |
Why?
|
| Benzimidazoles | 1 | 2014 | 151 | 0.390 |
Why?
|
| Risk Factors | 10 | 2025 | 10636 | 0.380 |
Why?
|
| Hypertension | 3 | 2024 | 1336 | 0.380 |
Why?
|
| Multidetector Computed Tomography | 1 | 2012 | 33 | 0.360 |
Why?
|
| Congresses as Topic | 3 | 2025 | 175 | 0.360 |
Why?
|
| Vascular Calcification | 1 | 2012 | 65 | 0.340 |
Why?
|
| Thrombosis | 2 | 2014 | 503 | 0.340 |
Why?
|
| Coronary Artery Disease | 2 | 2022 | 850 | 0.340 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2020 | 430 | 0.330 |
Why?
|
| Coronary Angiography | 1 | 2012 | 452 | 0.300 |
Why?
|
| Heart Neoplasms | 2 | 2016 | 105 | 0.280 |
Why?
|
| Aortic Valve | 3 | 2024 | 444 | 0.260 |
Why?
|
| Aged | 9 | 2025 | 20512 | 0.250 |
Why?
|
| Prognosis | 4 | 2024 | 4803 | 0.250 |
Why?
|
| Humans | 25 | 2025 | 127501 | 0.230 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2025 | 14 | 0.220 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2024 | 7 | 0.220 |
Why?
|
| Academies and Institutes | 1 | 2025 | 80 | 0.210 |
Why?
|
| Carotid Artery, Internal | 1 | 2024 | 55 | 0.210 |
Why?
|
| Female | 17 | 2025 | 68765 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2048 | 0.210 |
Why?
|
| Risk Assessment | 5 | 2024 | 3596 | 0.210 |
Why?
|
| Evidence-Based Medicine | 3 | 2012 | 631 | 0.200 |
Why?
|
| Aging | 1 | 2011 | 1207 | 0.200 |
Why?
|
| Middle Aged | 13 | 2025 | 27886 | 0.200 |
Why?
|
| Depression | 1 | 2012 | 1296 | 0.190 |
Why?
|
| Calcinosis | 1 | 2024 | 184 | 0.190 |
Why?
|
| Texas | 3 | 2025 | 3564 | 0.190 |
Why?
|
| Cardiac Tamponade | 1 | 2002 | 37 | 0.180 |
Why?
|
| Treatment Outcome | 7 | 2024 | 12583 | 0.180 |
Why?
|
| Metabolic Syndrome | 1 | 2025 | 345 | 0.180 |
Why?
|
| Stroke Volume | 1 | 2023 | 514 | 0.170 |
Why?
|
| Male | 14 | 2025 | 62895 | 0.170 |
Why?
|
| Prevalence | 3 | 2024 | 2623 | 0.170 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 6716 | 0.150 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 2240 | 0.140 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2008 | 72 | 0.130 |
Why?
|
| Adult | 6 | 2025 | 30603 | 0.130 |
Why?
|
| Sex Factors | 2 | 2011 | 1314 | 0.130 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2017 | 109 | 0.130 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 2999 | 0.120 |
Why?
|
| Algorithms | 1 | 2022 | 1638 | 0.110 |
Why?
|
| Myocardial Infarction | 3 | 2008 | 979 | 0.110 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 264 | 0.110 |
Why?
|
| Melanoma | 1 | 2002 | 898 | 0.110 |
Why?
|
| Hospitalization | 1 | 2023 | 1878 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 152 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2024 | 17080 | 0.110 |
Why?
|
| Atherosclerosis | 1 | 2022 | 930 | 0.110 |
Why?
|
| Age Factors | 2 | 2011 | 2814 | 0.110 |
Why?
|
| Dabigatran | 1 | 2014 | 26 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 1148 | 0.100 |
Why?
|
| Prenatal Diagnosis | 1 | 2017 | 634 | 0.100 |
Why?
|
| Myocardial Ischemia | 2 | 2012 | 301 | 0.090 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2012 | 41 | 0.090 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 77 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 1206 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2012 | 126 | 0.090 |
Why?
|
| Comorbidity | 1 | 2016 | 1563 | 0.090 |
Why?
|
| Propensity Score | 1 | 2012 | 250 | 0.080 |
Why?
|
| Preventive Health Services | 1 | 2011 | 57 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 231 | 0.080 |
Why?
|
| Postmenopause | 1 | 2011 | 141 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2012 | 314 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 145 | 0.080 |
Why?
|
| Primary Prevention | 1 | 2011 | 173 | 0.080 |
Why?
|
| Secondary Prevention | 1 | 2011 | 219 | 0.080 |
Why?
|
| Myocardium | 2 | 2016 | 845 | 0.070 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2012 | 823 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 574 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2012 | 393 | 0.070 |
Why?
|
| Body Size | 1 | 2008 | 59 | 0.070 |
Why?
|
| Coronary Artery Bypass | 1 | 2012 | 525 | 0.070 |
Why?
|
| Protein C Deficiency | 1 | 2007 | 10 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2012 | 1050 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1110 | 0.060 |
Why?
|
| Coronary Circulation | 1 | 2007 | 188 | 0.060 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2007 | 124 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 2007 | 140 | 0.060 |
Why?
|
| Hypoxia | 1 | 2007 | 243 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1277 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3721 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2008 | 1500 | 0.050 |
Why?
|
| Heart Atria | 2 | 2007 | 324 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 209 | 0.050 |
Why?
|
| Pericarditis | 1 | 2003 | 44 | 0.050 |
Why?
|
| Young Adult | 1 | 2016 | 9702 | 0.050 |
Why?
|
| Life Style | 1 | 2025 | 436 | 0.050 |
Why?
|
| Dyslipidemias | 1 | 2024 | 235 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 3937 | 0.040 |
Why?
|
| Pericardial Effusion | 1 | 2002 | 71 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2002 | 359 | 0.040 |
Why?
|
| Endocardium | 2 | 2012 | 46 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2012 | 3076 | 0.040 |
Why?
|
| Self Report | 1 | 2022 | 537 | 0.040 |
Why?
|
| Stents | 1 | 2024 | 770 | 0.040 |
Why?
|
| Dogs | 2 | 2008 | 614 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2020 | 413 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2008 | 642 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2002 | 968 | 0.030 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 753 | 0.030 |
Why?
|
| United States | 1 | 2011 | 11425 | 0.030 |
Why?
|
| Obesity | 1 | 2024 | 2338 | 0.020 |
Why?
|
| Body Surface Potential Mapping | 1 | 2012 | 13 | 0.020 |
Why?
|
| Injections | 1 | 2012 | 114 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 97 | 0.020 |
Why?
|
| Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography | 1 | 2011 | 2 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 265 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2011 | 60 | 0.020 |
Why?
|
| Morbidity | 1 | 2012 | 252 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2011 | 236 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 5161 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1310 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2008 | 19 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 755 | 0.020 |
Why?
|
| Fibronectins | 1 | 2008 | 99 | 0.020 |
Why?
|
| Laminin | 1 | 2008 | 67 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1602 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2008 | 154 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1406 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2008 | 223 | 0.020 |
Why?
|
| Collagen | 1 | 2008 | 292 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2007 | 115 | 0.020 |
Why?
|
| Thrombectomy | 1 | 2007 | 105 | 0.020 |
Why?
|
| Warfarin | 1 | 2007 | 122 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2007 | 252 | 0.010 |
Why?
|
| Pregnancy | 1 | 2017 | 7426 | 0.010 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2007 | 369 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 2400 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2007 | 524 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2007 | 442 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2007 | 581 | 0.010 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2003 | 172 | 0.010 |
Why?
|
| Quality of Life | 1 | 2011 | 2032 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 6247 | 0.010 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2007 | 1161 | 0.010 |
Why?
|
| Animals | 2 | 2008 | 33212 | 0.010 |
Why?
|